"CMS and HHS stated their intent to issue new rulemaking and to exercise enforcement discretion pending issuance of a final new rule, which likely reduces the associated risk of implementing or operating Accumulator Adjustment Programs in the short term.... [B]ecause the 2020 Accumulator Rule is currently in effect per the Court's decision, hubs, copay vendors, and drug manufacturers should prepare to comply with the rule and only utilize Accumulator Adjustment Programs, where allowed by state law, for branded drugs with a generic equivalent." [HIV and Hepatitis Policy Inst. v. HHS, No. 22-2604 (D.D.C. Sep. 29, 2023)]  MORE >>